Relationship between kisspeptin levels in the third trimester and late-onset fetal growth restriction: A case-control study.

Autor: Ibanoglu MC; Etlik Zubeyde Hanim Women's Health Education of Research Hospital, Department of Obstetrics and Gynecology, Turkey. Electronic address: drmujdecan@gmail.com., Oskovi-Kaplan ZA; Ministry of Health Ankara City Hospital, Department of Obstetrics and Gynecology, Turkey., Kara O; Ministry of Health Ankara City Hospital, Department of Obstetrics and Gynecology, Turkey., Ozgu-Erdinc AS; Ministry of Health Ankara City Hospital, Department of Obstetrics and Gynecology, Turkey., Şahin D; Ministry of Health Ankara City Hospital, Department of Perinatology, Turkey.
Jazyk: angličtina
Zdroj: Placenta [Placenta] 2023 Sep 07; Vol. 140, pp. 1-5. Date of Electronic Publication: 2023 Jul 20.
DOI: 10.1016/j.placenta.2023.07.012
Abstrakt: Introduction: We aimed to investigate whether maternal serum kisspeptin levels are associated with late-onset FGR and contribute to adverse perinatal outcomes.
Method: In this case-control study, a total of 90 pregnant women admitted to the perinatology clinic were enrolled. Forty-five of them were diagnosed with FGR and 45 women with healthy pregnancies formed the control group. Maternal serum levels of kisspeptin 1 were compared.
Results: Median kisspeptin1 serum levels were higher in the group of patients with FGR according to gestational age than in the control group [79.4(3.9-230.2) pg/mL vs. 39.8(0.4-188.3) pg/mL; p = 0.001]. The optimal cut-off value for kisspeptin1 was 30.32 pg/mL, with a positive predictive value of 64.6% (95% CI; 0.54-0.86), negative predictive value of 87.5% (95% CI; 0.44-0.72), positive likelihood ratio 1.75 (95% CI; 1.31-2.32), negative likelihood ratio 0.14 (95% CI; 0.04-0.44).
Discussion: Kisspeptin1 differed significantly in late-onset FGR compared with the control group. This difference from the control group can be used to estimate late-onset FGR.
Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: